Paper
Effects of the 5 alpha‐reductase inhibitor dutasteride on gene expression in prostate cancer xenografts
Published Dec 1, 2009 · L. Schmidt, Kevin M. Regan, S. K. Anderson
The Prostate
19
Citations
0
Influential Citations
Abstract
In the prostate, androgens play a crucial role in normal and cancerous growth; hence the androgenic pathway has become a target of therapeutic intervention. Dutasteride is a 5 alpha‐reductase (5AR) inhibitor currently being evaluated both for chemoprevention and treatment of prostate cancer. Dutasteride inhibits both 5AR I and II enzymes, effectively blocking conversion of testosterone to dihydrotestosterone (DHT) in the prostate. This greatly reduces the amount of the active ligand DHT available for binding to the androgen receptor (AR) and stimulating proliferation, making this a good candidate for chemoprevention of prostate cancer. In this study, we sought to determine how dutasteride is functioning at the molecular level, using a prostate cancer xenograft model.
Dutasteride effectively reduces testosterone to dihydrotestosterone in prostate cancer xenografts, potentially preventing prostate cancer by inhibiting androgen-dependent growth.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...